Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3CNS 3NET 2Gastrointestinal 1

Conditions

Glioma 9Neuroblastoma 8Breast Neoplasms 6Neoplasms 5Thyroid Cancer, Papillary 4Sarcoma 4Neurofibroma, Plexiform 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Thyroid Neoplasms 3Pheochromocytoma 3Paraganglioma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Diseases 2Thoracic Neoplasms 2Salivary Gland Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neuroendocrine Tumors 2Neoplasms by Site 2

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1belzutifan 1Lutetium-177 1Lutetium 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Pheochromocytoma × CNS × Clear all
NCT04924075 2026-05-11

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡